pembrolizumab + doxorubicin + vinblastine + dacarbazine

This combination drug regimen consists of **pembrolizumab**, **doxorubicin**, **vinblastine**, and **dacarbazine**, primarily studied for the treatment of classic Hodgkin lymphoma. Pembrolizumab is a monoclonal antibody that targets programmed cell death protein 1 (PD-1), enhancing T-cell mediated immune responses against cancer cells. Doxorubicin is an anthracycline antibiotic that intercalates DNA, inhibiting topoisomerase II and generating free radicals to induce apoptosis. Vinblastine is a vinca alkaloid that inhibits microtubule formation, thereby arresting mitosis. Dacarbazine is an alkylating agent that causes DNA methylation and cross-linking, leading to apoptosis. When administered together, these drugs provide a combination of immunotherapy and cytotoxic chemotherapy aimed at eliciting durable responses in Hodgkin lymphoma, with ongoing trials evaluating safety and efficacy[1][6][8][10].

Brand names

Keytruda

Other names

APVD